4D Molecular Therapeutics (NASDAQ:FDMT) Releases Quarterly Earnings Results, Misses Expectations By $0.01 EPS

4D Molecular Therapeutics (NASDAQ:FDMTGet Rating) released its quarterly earnings data on Thursday. The company reported ($0.82) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.81) by ($0.01), MarketWatch Earnings reports.

Shares of FDMT traded down $0.41 during trading hours on Friday, reaching $9.01. 412,801 shares of the company traded hands, compared to its average volume of 180,019. The stock’s fifty day moving average is $13.55 and its 200 day moving average is $17.27. 4D Molecular Therapeutics has a 1-year low of $8.93 and a 1-year high of $36.14.

A number of hedge funds and other institutional investors have recently bought and sold shares of FDMT. State Street Corp increased its stake in 4D Molecular Therapeutics by 294.1% in the fourth quarter. State Street Corp now owns 1,259,660 shares of the company’s stock valued at $27,637,000 after acquiring an additional 939,998 shares during the period. BlackRock Inc. increased its stake in 4D Molecular Therapeutics by 45.1% in the fourth quarter. BlackRock Inc. now owns 2,087,682 shares of the company’s stock valued at $45,803,000 after acquiring an additional 649,319 shares during the period. Morgan Stanley increased its stake in 4D Molecular Therapeutics by 58.3% in the second quarter. Morgan Stanley now owns 430,787 shares of the company’s stock valued at $10,374,000 after acquiring an additional 158,641 shares during the period. Geode Capital Management LLC increased its stake in 4D Molecular Therapeutics by 41.0% in the fourth quarter. Geode Capital Management LLC now owns 482,437 shares of the company’s stock valued at $10,584,000 after acquiring an additional 140,219 shares during the period. Finally, JPMorgan Chase & Co. increased its stake in 4D Molecular Therapeutics by 29.7% in the first quarter. JPMorgan Chase & Co. now owns 367,545 shares of the company’s stock valued at $5,557,000 after acquiring an additional 84,158 shares during the period. 76.60% of the stock is currently owned by institutional investors and hedge funds.

Separately, Zacks Investment Research lowered shares of 4D Molecular Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, April 6th.

4D Molecular Therapeutics Company Profile (Get Rating)

4D Molecular Therapeutics, Inc, a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease.

Read More

Earnings History for 4D Molecular Therapeutics (NASDAQ:FDMT)

Receive News & Ratings for 4D Molecular Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 4D Molecular Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.